BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today ...
This article and associated images are based on a poster originally authored by Paulina Chorobik, Maciej B. Olszewski, John Vincent and Kirsty Winn and presented at ELRIG Drug Discovery 2025 in ...
--One patient in cohort 4A with stage 4 KRAS G12R mutated pancreatic cancer achieves over 5 months of stable disease with tumor volume reduction of -9.8% -- MIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- ...
QurAlis intends to advance QRL-101 into Phase 2 proof-of-concept clinical trials as a potentially best-in-class treatment for both DEE and ALS QurAlis Corporation (“QurAlis”), a clinical-stage ...
First-in-human study evaluates safety, pharmacokinetics, biomarker analyses, target engagement, and anti-tumor activity in ...
4M Therapeutics Inc. has released new preclinical data for its lead program, 4MT-2001, a novel small-molecule glycogen synthase kinase 3β (GSK-3β) inhibitor, demonstrating central nervous system (CNS) ...
QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback